Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Weighted Average)
Others
Ratios

KalVista Pharmaceuticals (KALV) Research & Development: 2013-2025

Historic Research & Development for KalVista Pharmaceuticals (KALV) over the last 13 years, with Apr 2025 value amounting to $71.7 million.

  • KalVista Pharmaceuticals' Research & Development fell 34.21% to $16.6 million in Q2 2025 from the same period last year, while for Apr 2025 it was $91.0 million, marking a year-over-year increase of 32.86%. This contributed to the annual value of $71.7 million for FY2025, which is 16.78% down from last year.
  • Per KalVista Pharmaceuticals' latest filing, its Research & Development stood at $71.7 million for FY2025, which was down 16.78% from $86.2 million recorded in FY2024.
  • In the past 5 years, KalVista Pharmaceuticals' Research & Development ranged from a high of $86.2 million in FY2024 and a low of $41.3 million during FY2021.
  • In the last 3 years, KalVista Pharmaceuticals' Research & Development had a median value of $80.3 million in 2023 and averaged $79.4 million.
  • As far as peak fluctuations go, KalVista Pharmaceuticals' Research & Development soared by 69.95% in 2022, and later fell by 16.78% in 2025.
  • Over the past 5 years, KalVista Pharmaceuticals' Research & Development (Yearly) stood at $41.3 million in 2021, then skyrocketed by 69.95% to $70.2 million in 2022, then climbed by 14.41% to $80.3 million in 2023, then rose by 7.34% to $86.2 million in 2024, then fell by 16.78% to $71.7 million in 2025.